Description

Naltrexone Hydrochloride USP/EP

Naltrexone HCl USP/EP is a pharmaceutical-grade opioid receptor antagonist used in oral and injectable pharmaceutical formulations for the treatment of alcohol dependence and opioid use disorder.

• It complies with USP and Ph. Eur. standards for API quality
• It inhibits μ-opioid receptors, supporting detox and maintenance therapy
• It is suitable for tablets, extended-release injectables, and depot systems
• It is manufactured under cGMP-compliant processes
• It is supplied with full regulatory documentation

Naltrexone HCl is a Hydrochloride salt form of Naltrexone that offers enhanced solubility and formulation versatility. It is widely used in both acute detoxification programs and long-term management of substance use disorders. It is typically formulated for oral use or extended-release injections that improve patient adherence.

Its antagonistic action at opioid receptors prevents the euphoric effects of narcotics and has shown significant clinical value in reducing relapse rates. The compound is also explored for emerging use in combination therapies and novel delivery platforms.

CarboMer supplies high-purity Naltrexone HCl USP/EP in packaging suitable for all stages of product development, including commercial manufacturing. All batches are manufactured with full traceability and rigorous quality control.

The product is delivered in sealed containers designed to protect against light and moisture, ensuring optimal stability.

Comprehensive regulatory support is included. CarboMer’s technical team is available to support your formulation, scale-up, and submission processes.

As with all CarboMer APIs, Naltrexone HCl USP/EP is backed by robust compliance systems, scientific support, and a manufacturing-first mindset to help ensure your product’s success from development to market.